Sergliflozin etabonate
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Sergliflozin etabonate (
GlaxoSmithKline. It did not undergo further development after phase II.[citation needed
]
Method of action
Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3][4]
Chemistry
Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.
References
- ^ World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59" (PDF). WHO Drug Information. 22 (1): 66. Archived from the original (PDF) on February 19, 2009.
- ^ "Statement on a nonproprietary name adopted by the USAN council: Sergliflozin etabonate" (PDF). American Medical Association. Retrieved 2008-08-10.
- S2CID 8306408.
- ^ "Prous Science: Molecule of the Month November 2007". Archived from the original on 2007-11-05. Retrieved 2008-10-28.